Biomarkers of outcome in rheumatoid arthritis

Carrasco, Roberto; Barton, Anne

doi:10.4081/rr.2010.e3

Cited by 10 publications

(9 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA‐DRB1 can be a marker for RA severity and predict the possibility of erosion . Early diagnosis, risk factors identification and treatment are important in proper RA management…”

Section: Introductionmentioning

confidence: 99%

Study on association of human leukocyte antigen‐DRB1 alleles amongst Bangladeshi patients with rheumatoid arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…HLA‐DRB1 can be a marker for RA severity and predict the possibility of erosion . Early diagnosis, risk factors identification and treatment are important in proper RA management…”

Section: Introductionmentioning

confidence: 99%

Study on association of human leukocyte antigen‐DRB1 alleles amongst Bangladeshi patients with rheumatoid arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Serum levels of MMP-3 in particular have previously been found to correlate with disease activity in RA and MMP-9 in systemic lupus erythematosus (SLE), which is another rheumatic disease [ 21 , 22 ]. MMP-3 and MMP-9 have also been found to contribute to inflammatory conditions in the skin [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment

Selaas

Nordal

Halse

et al. 2015

International Journal of Rheumatology

View full text Add to dashboard Cite

Objective. The aim of this study was to investigate the clinical effect and serum markers in a cohort of rheumatoid arthritis patients with moderate to high disease activity, participating in an open clinical phase IV study conducted in Norway between 2001 and 2003 receiving infliximab treatment. Method. A total of 39 patients were studied, with a mean age of 54 years and 12-year disease duration. The analyses were performed using serum from patients at four assessment time points: baseline and 3, 6, and 12 months after starting treatment with infliximab. A wide variety of clinical data was collected and disease activity of 28 joints and Simple Disease Activity Index were calculated. The joint erosion was determined by X-ray imaging and the Sharp/van der Heijde score was determined. Serum analysis included multiplex immunoassays for 12 cytokines, 5 matrix metalloproteases, and 2 VEGFs. Results. The majority of the RA patients in this study had initially moderate to high disease activity and the infliximab treatment reduced the disease activity significantly and also reduced any further joint destruction and improved disease status. Most of the serum levels of cytokines and metalloproteases remained unchanged during the course of the study, and we were unable to detect changes in TNF-α in serum. Serum levels of IL-6 and VEGF-A decreased significantly after initiation of infliximab treatment. Conclusion. The serum levels of IL-6 and VEGF-A may be promising disease markers as they vary with disease progression. The clinical significance of these findings is yet to be determined and has to be confirmed in future clinical trials before being applied in the clinics.

show abstract

“…Over the past decade, proteomics have yielded potential new candidates in the quest for better biomarkers for RA, including the S100 proteins, serum amyloid A, alpha 1-antitrypsin, and apolipoproteins in the blood [ 6 ]. In principle, carbohydrates, lipids and proteins (including enzymes, matrix proteins or their neoepitopes, autoantibodies, acute-phase proteins, chemokines, growth factors, cytokines and their inhibitors, and receptors) can be biomarkers for inflammation, connective tissue destruction, diagnosis and prognosis in RA (reviewed by Carrasco and Barton [ 7 ]).…”

Section: Biomarkers Identified By-omicsmentioning

confidence: 99%

Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis?

Loo

2011

Arthritis Res Ther

View full text Add to dashboard Cite

It has long been recognized that laboratory tests are useful in the diagnosis of disease and to monitor treatment outcome. Their performance has become even more demanding with the development of personalized medicine. In patients with rheumatoid arthritis (RA) the standard biochemical tests measure serological markers of disease, such as C-reactive protein, and RA-associated auto-antibodies, such as rheumatoid factor and anti-citrullinated protein antibodies. The information obtained from these markers does not, however, provide a complete picture of the disease and treatment efficacy. New biomarkers based on cytokine receptor complexes are promising for RA theragnostics.

show abstract

Biomarkers of outcome in rheumatoid arthritis

Abstract: No Abstrac

Cited by 10 publications

References 150 publications

Study on association of human leukocyte antigen‐DRB1 alleles amongst Bangladeshi patients with rheumatoid arthritis

Study on association of human leukocyte antigen‐DRB1 alleles amongst Bangladeshi patients with rheumatoid arthritis

Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment

Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis?

Contact Info

Product

Resources

About